Cue Biopharma, Inc. (CUE) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing therapeutic biologics to modulate T cells for oncology and autoimmune diseases. This report covers the quarterly period ended June 30, 2024. The company is classified as a smaller reporting company and a non-accelerated filer. As of August 9, 2024, there were 48,643,316 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $2,658 | $1,382 | $4,375 | $1,570 |
| Total Operating Expenses | $13,041 | $14,899 | $27,426 | $28,466 |
| Net Loss | $(10,171) | $(13,185) | $(22,518) | $(26,294) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.29) | $(0.45) | $(0.59) |
| Cash and Cash Equivalents (End of Period) | $30,029 (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities (YTD) | $(19,774) | |||
| Long-Term Debt (Net) | $2,286 (Current portion: $3,963) |
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased significantly, driven by the Ono Collaboration and Option Agreement. YTD revenue rose from $1.6 million in 2023 to $4.4 million in 2024.
- Expense Reduction: Total operating expenses decreased by approximately $1.9 million YTD compared to the prior year, primarily due to reductions in professional fees, employee compensation, and stock-based compensation.
- Improved Loss Profile: Net loss narrowed by approximately $3.8 million YTD compared to the same period in 2023, reflecting both revenue growth and cost containment.
- Cash Position: Cash and cash equivalents declined from $48.5 million at year-end 2023 to $30.0 million at June 30, 2024, due to operating cash burn and debt repayments.
Guidance, Outlook, and Risks
- Strategic Pivot: In July 2024, management announced a strategic prioritization of autoimmune programs (CUE-401 and CUE-501) and a 25% workforce reduction to improve operational efficiency. Oncology programs (CUE-101, CUE-102) are being deprioritized while seeking third-party partnerships.
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management estimates current cash resources will fund operations into the second quarter of 2025. Additional financing via equity offerings, collaborations, or debt is required.
- Debt Covenants: The company holds a $10 million term loan (outstanding principal $6.0 million) with First Citizens Bank. The agreement requires maintaining at least $20 million in unrestricted cash at the lender. As of June 30, 2024, the company held $30.0 million, remaining in compliance.
- Nasdaq Compliance: The company noted that its stock price closed below the $1.00 minimum bid price requirement from July 3, 2024, through the filing date, posing a risk of delisting if not corrected within 180 days.
- Collaboration Milestones: Revenue is heavily dependent on the Ono agreement (funding CUE-401) and the LG Chem agreement (oncology). No commercial product sales have been generated.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that cash will last into Q2 2025 given the recent 25% workforce reduction and potential delays in fundraising.
- Debt Covenant Compliance: Monitor the $20 million cash balance requirement at First Citizens Bank to ensure no event of default occurs as cash is depleted.
- Nasdaq Listing Status: Track the stock price to determine if the company receives a deficiency letter and its ability to regain compliance within the 180-day window.
- Partnership Progress: Assess the status of potential partnerships for the deprioritized oncology assets (CUE-101/CUE-102) to offset R&D costs.
- Ono Collaboration Terms: Review the specific milestones and funding caps under the Ono agreement to understand future revenue recognition potential.